CD274 and neoplasm: In short, there is an increasing emphasis on the potential contribution of innate immune effectors against tumor immunity, and the integration of multiple means of targeting the adaptive immune system into PD-1/PD-L1 inhibitor-based therapies may be a fundamental combination approach in immunotherapy in the future.